CHMP shakes head at Qsiva and memantine/donepezil combo
This article was originally published in Scrip
Executive Summary
The European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) has adopted negative opinions for Vivus's weight loss drug Qsiva, and a combination pill of memantine and donepezil for Alzheimer's disease filed by Lundbeck and Merz Pharmaceuticals as Acrescent and Balaxur, respectively.